Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104-4318, USA.
Pediatr Blood Cancer. 2013 Jun;60(6):1044-7. doi: 10.1002/pbc.24437. Epub 2012 Dec 19.
The role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi-institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant-associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN.
SCT 在儿科肿瘤学中的作用随着新的治疗药物和对癌症的免疫学认识的引入而不断发展。COG 专注于在几项主要的多机构 II 期和 III 期研究中研究造血干细胞移植治疗儿科恶性肿瘤。这些研究包括解决 ALL 中的异体性影响（ASCT0431），并将自体干细胞移植确立为神经母细胞瘤的标准治疗方法。ASCT0521 研究解决了与移植相关的毒性问题，其中 TNFα 抑制剂依那西普被测试用于治疗特发性肺炎综合征。与 BMT-CTN 密切合作，在单脐血与双脐血研究 CTN-0501 中探讨了细胞剂量的影响。
